Effect of Prophylactic Pancreatic Duct Stenting on Post-ERCP Pancreatitis in Patients With Risk Factors
10.3969/j.issn.1008-7125.2017.09.008
- VernacularTitle:胰管支架对伴有危险因素的患者发生ERCP术后胰腺炎的预防作用
- Author:
Guofa JIA
;
Hong SHAN
;
Liying WU
;
Di ZHANG
;
Jinzhi WANG
;
Xiaotian WANG
;
Liangsong ZHU
- Keywords:
Cholangiopancreatography,Endoscopic Retrograde;
Stents;
Post-ERCP Pancreatitis;
Hyperamylasemia;
Risk Factors
- From:
Chinese Journal of Gastroenterology
2017;22(9):548-552
- CountryChina
- Language:Chinese
-
Abstract:
Background:Pancreatitis is the main complication of ERCP,and a variety of risk factors will increase its risk. Studies showed that temporary pancreatic duct stent can reduce the incidence of post-ERCP pancreatitis (PEP). Aims:To study the efficacy and safety of prophylactic pancreatic duct stenting on preventing PEP in patients with risk factors. Methods:Patients undergone ERCP and accompanied with one or more PEP-associated risk factors from November 2013 to November 2016 at Huaibei People's Hospital were enrolled,and were divided randomly into pancreatic duct stenting group (observation group)and non-stenting group (control group). Serum levels of amylase at 4,24 and 48 hours after the procedure and incidence of PEP were compared between the two groups. Results:A total of 297 patients were enrolled, and 147 patients were in observation group,and 150 patients in control group. No significant differences in gender,age and ERCP disease spectrum were found between the two groups (P > 0. 05). Incidence of PEP was significantly decreased in observation group than in control group (6. 1％ vs. 16. 0％,P < 0. 05). Serum levels of amylase at 4,24 and 48 hours after the procedure were significantly decreased in observation group than in corresponding control group (P < 0. 05), however,no significant difference in incidence of hyperamylasemia was found between the two groups (59. 2％ vs. 54. 7％, P > 0. 05). Conclusions:Prophylactic pancreatic duct stenting may decrease the incidence of PEP in patients accompanied with PEP-associated risk factors, especially could decrease the severity of PEP. However, the incidence of hyperamylasemia is not decreased.
